Journal of Leukemia
Open Access

Issa Hajji Ally

Publications

• Review Article
  Treatment Advances for Burkitt Lymphoma
  Author(s): Issa Hajji Ally, Ting Yang and Jianda HuIssa Hajji Ally, Ting Yang and Jianda Hu
  
  Burkitt Lymphoma (BL) is an uncommon but highly aggressive B-cell Non-Hodgkin Lymphoma (NHL). It is a subtype of mature B-cell lymphoma and can be treated successfully within a short period via high-intensity chemotherapeutic regimens. Diagnosis and initial work-up must be completed rapidly to begin treatment due to high proliferation. BL is associated with the Epstein-Barr Virus (EBV) and with a chromosomal translocation that activates the c-MYC gene. However, by implementing chemotherapy regimens, complete remission and overall survival for young patients with BL remains high. In contrast, in elderly patients and those with relapsed/refractory disease, the prognosis remains a medical challenge. Rituximab, the chimeric monoclonal antibody against CD20, has improved the clinical management of B-cell malignancies. Because BL expresses a CD20 positive marker in their cell surface.. View More»
  DOI: 10.35248/2329-6917.19.7.255

  Abstract PDF

Relevant Topics